Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Deferred Taxes (2016 - 2020)

Enanta Pharmaceuticals filings provide 7 years of Deferred Taxes readings, the most recent being $15.0 million for Q3 2020.

  • On a quarterly basis, Deferred Taxes rose 1363.63% to $15.0 million in Q3 2020 year-over-year; TTM through Sep 2020 was $10.6 million, a 438.05% increase, with the full-year FY2021 number at $345000.0, down 96.75% from a year prior.
  • Deferred Taxes hit $15.0 million in Q3 2020 for Enanta Pharmaceuticals, up from -$3.1 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $15.0 million in Q3 2020 to a low of -$3.8 million in Q2 2017.
  • Median Deferred Taxes over the past 5 years was -$918000.0 (2018), compared with a mean of $263052.6.
  • Biggest five-year swings in Deferred Taxes: plummeted 5816.67% in 2016 and later surged 1363.63% in 2020.
  • Enanta Pharmaceuticals' Deferred Taxes stood at -$1.9 million in 2016, then skyrocketed by 239.37% to $2.7 million in 2017, then crashed by 134.49% to -$918000.0 in 2018, then skyrocketed by 171.57% to $657000.0 in 2019, then surged by 2179.15% to $15.0 million in 2020.
  • The last three reported values for Deferred Taxes were $15.0 million (Q3 2020), -$3.1 million (Q2 2020), and -$1.9 million (Q1 2020) per Business Quant data.